Astex is also expanding the evaluation of cedazuridine – decitabine combinations through a program of investigator-sponsored trials. ASTX727 is an investigational compound and is not currently ...

Astex Pharmaceuticals, Inc., a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co., Ltd., today announce top-line results of the AS ...

As part of the agreement, Astex has taken an equity stake in Mosaic equating to a fully-diluted ownership stake of 19% equity upfront and a further 3% dependent on clinical milestones, which will ...

Astex Pharmaceuticals knows a thing or two about working with a Big Pharma from lab to blockbuster status. Now, the British company is adding another line to a Merck & Co. cancer collaboration ...

GSK Signs On Astex in Broad Partnership for About $33M Up Front. GlaxoSmithKline (GSK) has inked a deal with Astex Therapeutics to discover, develop, and commercialize compounds directed against ...

Astex is a leading proponent of fragment-based drug discovery (FBDD), an approach with a couple of market approvals already under its belt that has become increasingly popular over the past decade ...

Astex Pharmaceuticals Inc. is getting $35 million up front and up to $500 million per program as it extends its drug discovery collaboration with Merck & Co. Inc. to include small-molecule activators ...

Astex Therapeutics has signed a cancer drug research deal with Johnson & Johnson <JNJ.N> potentially worth more than $500 million (253 million pounds) in milestone payments, it said on Monday.

Astex will hand off marketing duties to Taiho Oncology, its sister company under the Otsuka umbrella. With an oncology salesforce locked into place—and prior experience bringing another oral ...

Japanese drugmaker Otsuka Holdings Co has agreed to buy Astex Pharmaceuticals Inc for about $886 million to tap cancer drugs under development by the U.S. biotechnology company.

As part of the agreement, Astex has taken an equity stake in Mosaic equating to a fully-diluted ownership stake of 19% equity upfront and a further 3% dependent on clinical milestones, which will ...

Astex will also receive potential future revenue shares. Dr. Harren Jhoti, Co-founder, President and Chief Executive Officer of Astex, will also take an observer role on the Mosaic Board.